Can ProKidney Survive Until Its Only Data Point Arrives?
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Dec 2025 | $-0.16 | $-0.14 | +12.50% | Beat |
| Mar 2026 | $-0.13 | $-0.14 | -7.69% | Miss |
| Jun 2026 | $-0.13 | $-0.15 | -15.38% | Miss |
| Sep 2026 | $-0.13 | $-0.17 | -30.77% | Miss |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
ProKidney has not disclosed the timing of its November 16 earnings release, but historical patterns suggest the company typically reports after market close.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-10 | +$0.05 (+3.05%) | $0.07 (4.57%) | -$0.08 (-4.73%) | $0.15 (8.88%) |
| 2026-05-15 | -$0.05 (-2.92%) | $0.14 (8.19%) | -$0.05 (-3.01%) | $0.13 (7.83%) |
| 2026-03-18 | -$0.05 (-2.35%) | $0.09 (4.23%) | -$0.13 (-6.25%) | $0.23 (11.06%) |
| 2025-11-10 | -$0.19 (-6.57%) | $0.29 (9.86%) | +$0.10 (+3.70%) | $0.14 (5.16%) |
| 2025-08-12 | -$0.01 (-0.67%) | $0.15 (6.65%) | +$0.13 (+5.80%) | $0.27 (11.83%) |
| 2025-05-12 | +$0.03 (+3.96%) | $0.08 (11.62%) | +$0.12 (+15.79%) | $0.11 (14.60%) |
| 2025-03-17 | +$0.06 (+5.73%) | $0.10 (10.26%) | -$0.07 (-6.77%) | $0.10 (9.49%) |
| 2024-11-12 | -$0.10 (-4.65%) | $0.20 (9.30%) | +$0.02 (+0.98%) | $0.24 (11.67%) |
| Avg Abs Move | 3.74% | 8.08% | 5.88% | 10.06% |
ProKidney's post-earnings price action has been volatile but relatively muted compared to typical biotech swings. Over the past eight quarters, the stock has averaged an absolute move of 3.74% on earnings day and 5.88% the following session, with intraday ranges averaging 8.08% and 10.06%, respectively.
The most dramatic reaction came in November 2025, when the stock dropped 6.57% on earnings day before rebounding 3.70% the next session. More recently, the August 2026 report saw a modest 3.05% gain on Day 0 followed by a 4.73% decline on Day +1. The May 2026 and March 2026 reports both triggered initial declines of roughly 3%, with the March report leading to a sharper 6.25% drop the following day.
The pattern suggests investors react more to forward guidance and clinical updates than to the quarterly loss figures themselves. Given the tight cash runway and the proximity to the pivotal Q2 2027 data readout, any commentary on trial progress, enrollment, or financing plans could drive outsized volatility this time around.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| Aug 2026 | +$0.05 (+3.05%) | $0.07 (4.57%) | -$0.08 (-4.73%) | $0.15 (8.88%) |
| May 2026 | -$0.05 (-2.92%) | $0.14 (8.19%) | -$0.05 (-3.01%) | $0.13 (7.83%) |
| Mar 2026 | -$0.05 (-2.35%) | $0.09 (4.23%) | -$0.13 (-6.25%) | $0.23 (11.06%) |
| Nov 2025 | -$0.19 (-6.57%) | $0.29 (9.86%) | +$0.10 (+3.70%) | $0.14 (5.16%) |
| Aug 2025 | -$0.01 (-0.67%) | $0.15 (6.65%) | +$0.13 (+5.80%) | $0.27 (11.83%) |
| May 2025 | +$0.03 (+3.96%) | $0.08 (11.62%) | +$0.12 (+15.79%) | $0.11 (14.60%) |
| Mar 2025 | +$0.06 (+5.73%) | $0.10 (10.26%) | -$0.07 (-6.77%) | $0.10 (9.49%) |
| Nov 2024 | -$0.10 (-4.65%) | $0.20 (9.30%) | +$0.02 (+0.98%) | $0.24 (11.67%) |
| Avg Abs Move | 3.74% | 8.08% | 5.88% | 10.06% |
Part 3: What Analysts Are Saying
Analyst sentiment on ProKidney is cautiously optimistic but deeply divided. The stock carries a Buy rating on average (4.00 on a 5-point scale), with 4 Strong Buy ratings, 2 Hold ratings, and 1 Moderate Sell rating among the 7 analysts covering the stock. Sentiment has improved over the past month, with one analyst upgrading from Hold to Strong Buy.
The average price target of $6.50 implies substantial upside from current levels, though the wide range—from a low of $1.00 to a high of $12.00—reflects the binary nature of the investment thesis. The bull case hinges on successful Phase 3 data and accelerated FDA approval, while the bear case centers on execution risk, cash constraints, and uncertainty around the regulatory pathway.
The consensus view is that ProKidney offers significant upside if the PROACT 1 trial succeeds, but the path to approval is fraught with risk. The improved sentiment over the past month suggests analysts are gaining confidence as the company approaches the pivotal Q2 2027 readout, but the Hold and Sell ratings underscore lingering concerns about valuation, cash burn, and the long timeline to commercialization.
Part 4: Technical Picture
ProKidney's technical setup heading into earnings is deeply bearish. The Barchart Technical Opinion stands at 100% Sell, unchanged over the past week and month, signaling maximum bearish conviction. The stock is trading below all key moving averages, with the current price of $1.05 sitting well below the 5-day ($1.12), 10-day ($1.11), 20-day ($1.27), 50-day ($1.53), 100-day ($1.60), and 200-day ($1.76) moving averages. This downward cascade reflects sustained selling pressure and a lack of technical support.
Timeframe Analysis:
- Short-term (100% Sell): Maximum sell signal indicates severe near-term weakness, with the stock in a steep downtrend and no signs of stabilization.
- Medium-term (100% Sell): Intermediate timeframe confirms the bearish trend, with no relief in sight as the stock continues to make lower lows.
- Long-term (100% Sell): The longer-term trend is equally negative, reflecting sustained erosion of investor confidence as the company burns cash and approaches a critical funding decision.
Trend Characteristics: The Maximum strength and Strongest direction of the sell signal indicate an entrenched downtrend with no technical support in sight. Heading into earnings, the setup suggests the stock is vulnerable to further downside if the company fails to provide reassurance on cash runway, trial progress, or financing plans.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $1.1170 | 50-Day MA | $1.5297 |
| 10-Day MA | $1.1100 | 100-Day MA | $1.5989 |
| 20-Day MA | $1.2687 | 200-Day MA | $1.7649 |
The stock is trading below all major moving averages, with no technical support visible. The 50-day moving average at $1.53 and the 200-day at $1.76 represent overhead resistance levels that would need to be reclaimed to signal any reversal. The relentless selling pressure reflects investor concerns about the company's cash position, the long wait for Phase 3 data, and the risk of dilutive financing. Unless management delivers a strong update on trial progress or announces a non-dilutive financing solution, the technical picture suggests the path of least resistance remains to the downside.